PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29762990-0	2017	[Tacrolimus down-regulates the mRNA levels of IL-17 and IL-23 in the muscle tissues of mice with experimental autoimmune myositis].	Tacrolimus	1-11	interleukin 17A	Mus musculus	46-51	
32563057-6	2020	Systemic MDSC plus FK-506 therapy was found to have a significant anti-psoriatic effect in the murine model, to reduce levels of pro-inflammatory cytokines Th1 cytokines (TNF-alpha and IFN-gamma) and Th17 cytokines (IL-17A and IL-23) in serum and skin.	Tacrolimus	19-25	interleukin 17A	Mus musculus	216-222	
34367377-14	2021	Serum protein expressions of IL-17 (p = 0.0017), IL-18 (p = 0.0036), IFN-gamma (p = 0.0102), and MMP-9 (p = 0.0194) were significantly decreased in the allograft+tacrolimus+azithromycin group compared to the allograft group.	Tacrolimus	162-172	interleukin 17A	Mus musculus	29-34	
27644556-6	2016	Secretion of IL-13 and IL-17A in CD4(+) T cells was lower in DHA/EPA- and FK506-treated mice than in mice treated with FK506 alone.	Tacrolimus	74-79	interleukin 17A	Mus musculus	23-29	
27644556-6	2016	Secretion of IL-13 and IL-17A in CD4(+) T cells was lower in DHA/EPA- and FK506-treated mice than in mice treated with FK506 alone.	Tacrolimus	119-124	interleukin 17A	Mus musculus	23-29	
21518963-2	2011	Tacrolimus treatment of mice for 1 week dose-dependently decreased splenic CD4(+)/FoxP3(+) (regulatory T cells), increased splenic CD4(+)/IL-17(+) (T-helper 17) cells, and caused endothelial dysfunction and hypertension.	Tacrolimus	0-10	interleukin 17A	Mus musculus	138-143